[go: up one dir, main page]

WO2005117991A3 - Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells - Google Patents

Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells Download PDF

Info

Publication number
WO2005117991A3
WO2005117991A3 PCT/US2005/015574 US2005015574W WO2005117991A3 WO 2005117991 A3 WO2005117991 A3 WO 2005117991A3 US 2005015574 W US2005015574 W US 2005015574W WO 2005117991 A3 WO2005117991 A3 WO 2005117991A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
nucleic acids
methods
target genes
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/015574
Other languages
French (fr)
Other versions
WO2005117991A2 (en
Inventor
Lishan Chen
Kunyuan Cui
Yuching Chen
Sasha J Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Priority to EP05804803A priority Critical patent/EP1750775A2/en
Priority to JP2007511576A priority patent/JP2007536253A/en
Priority to CA002565685A priority patent/CA2565685A1/en
Priority to MXPA06012605A priority patent/MXPA06012605A/en
Publication of WO2005117991A2 publication Critical patent/WO2005117991A2/en
Anticipated expiration legal-status Critical
Publication of WO2005117991A3 publication Critical patent/WO2005117991A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells. The transported nucleic acids are active in target cells as small inhibitory nucleic acids (siNAs) that modulate expression of target genes, mediated at least in part by RNA interference (RNAi). The siNA/polypeptide compositions and methods of the invention provide effective tools to modulate gene expression and alter phenotype in mammalian cells, including by altering phenotype in a manner that eliminates disease symptoms or alters disease potential in targeted cells or subject individuals to which the siNA/polypeptide compositions are administered.
PCT/US2005/015574 2004-05-04 2005-05-04 Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells Ceased WO2005117991A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05804803A EP1750775A2 (en) 2004-05-04 2005-05-04 Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
JP2007511576A JP2007536253A (en) 2004-05-04 2005-05-04 Compositions and methods for enhancing delivery of nucleic acids into cells and modifying expression of target genes in cells
CA002565685A CA2565685A1 (en) 2004-05-04 2005-05-04 Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
MXPA06012605A MXPA06012605A (en) 2004-05-04 2005-05-04 Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells.

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US56802704P 2004-05-04 2004-05-04
US60/568,027 2004-05-04
US57051204P 2004-05-12 2004-05-12
US57051304P 2004-05-12 2004-05-12
US60/570,513 2004-05-12
US60/570,512 2004-05-12
US61341604P 2004-09-27 2004-09-27
US60/613,416 2004-09-27
US65657205P 2005-02-25 2005-02-25
US60/656,572 2005-02-25
US66783305P 2005-04-01 2005-04-01
US60/667,833 2005-04-01

Publications (2)

Publication Number Publication Date
WO2005117991A2 WO2005117991A2 (en) 2005-12-15
WO2005117991A3 true WO2005117991A3 (en) 2007-01-18

Family

ID=35311390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/015574 Ceased WO2005117991A2 (en) 2004-05-04 2005-05-04 Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells

Country Status (5)

Country Link
EP (1) EP1750775A2 (en)
JP (1) JP2007536253A (en)
CA (1) CA2565685A1 (en)
MX (1) MXPA06012605A (en)
WO (1) WO2005117991A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
ES2500921T3 (en) 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Compositions to enhance the transport and antisense efficacy of nucleic acid analogs in cells
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
AU2006287481A1 (en) * 2005-09-08 2007-03-15 Mdrna, Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
JP2009514877A (en) * 2005-11-04 2009-04-09 エムディーアールエヌエー，インコーポレイテッド Peptide-Dither substrate RNA conjugates as siRNA delivery vehicles
JP2009520039A (en) * 2005-12-19 2009-05-21 サーナ・セラピューティクス・インコーポレイテッド Inhibition of hepatitis C virus (HCV) gene expression mediated by RNA interference using small interfering nucleic acids (siNA)
EP2046964B1 (en) * 2006-07-12 2018-07-04 The Regents of The University of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn Structure and use of 5' phosphate oligonucleotides
CA2661093A1 (en) * 2006-08-18 2008-02-21 Nastech Pharmaceutical Company Inc. Dicer substrate rna peptide conjugates and methods for rna therapeutics
KR20080076622A (en) * 2007-02-16 2008-08-20 포항공과대학교 산학협력단 Oligomerized Protein Carrier and Intracellular Virus Vector Delivery Method Using the Same
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
CN101946001A (en) * 2007-12-20 2011-01-12 安吉奥开米公司 Polypeptide-nucleic acid conjugates and uses thereof
JP5689413B2 (en) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 5 'triphosphate oligonucleotide having blunt ends and uses thereof
EP2681315B1 (en) * 2011-03-03 2017-05-03 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2834128A1 (en) * 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
HK1208682A1 (en) 2012-08-20 2016-03-11 The Regents Of The University Of California Polynucleotides having bioreversible groups
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
HUE054698T2 (en) * 2013-04-10 2021-09-28 Isd Immunotech Aps Use of immune suppressive domains as medicaments
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CA3033867A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
CN116949044B (en) * 2023-09-20 2023-12-12 北京炫景瑞医药科技有限公司 Double-stranded oligonucleotide, conjugate comprising double-stranded oligonucleotide and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070897A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003106491A2 (en) * 2002-06-18 2003-12-24 Cepep Ab Cell penetrating peptides
WO2004007721A1 (en) * 2002-07-17 2004-01-22 University Of Otago Conjugate for double-stranded rna sequence releasing and methods thereof
US20040019008A1 (en) * 2002-05-28 2004-01-29 Lewis David L. Compositions and processes using siRNA, amphipathic compounds and polycations
WO2004048545A2 (en) * 2002-11-26 2004-06-10 University Of Massachusetts DELIVERY OF siRNAs______________________________________________

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3581877B2 (en) * 1995-05-12 2004-10-27 独立行政法人産業技術総合研究所 Functional molecular transporter
US20030092180A1 (en) * 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
JPH1121255A (en) * 1997-07-02 1999-01-26 Hisamitsu Pharmaceut Co Inc Functional molecule transporter and its production
RU2002130200A (en) * 2000-04-12 2004-03-27 Импликс Лтд. (Gb) COMPOSITIONS FOR THE DELIVERY OF THE MEDICINE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070897A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040019008A1 (en) * 2002-05-28 2004-01-29 Lewis David L. Compositions and processes using siRNA, amphipathic compounds and polycations
WO2003106491A2 (en) * 2002-06-18 2003-12-24 Cepep Ab Cell penetrating peptides
WO2004007721A1 (en) * 2002-07-17 2004-01-22 University Of Otago Conjugate for double-stranded rna sequence releasing and methods thereof
WO2004048545A2 (en) * 2002-11-26 2004-06-10 University Of Massachusetts DELIVERY OF siRNAs______________________________________________

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "GALACTOSYLATED HISTONE-MEDIATED GENE TRANSFER AND EXPRESSION", HUMAN GENE THERAPY, vol. 5, 1994, pages 429 - 435, XP000199161, ISSN: 1043-0342 *
FERNANDEZ-CARNEADO JIMENA ET AL: "Amphipathic peptides and drug delivery", BIOPOLYMERS, vol. 76, no. 2, 8 March 2004 (2004-03-08), pages 196 - 203, XP002398047, ISSN: 0006-3525 *
HEBERT ERIC: "Improvement of exogenous DNA nuclear importation by nuclear localization signal-bearing vectors: A promising way for non-viral gene therapy?", BIOLOGY OF THE CELL (PARIS), vol. 95, no. 2, 2003, pages 59 - 68, XP002358850, ISSN: 0248-4900 *
MURATOVSKA A ET AL: "Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 558, no. 1-3, 30 January 2004 (2004-01-30), pages 63 - 68, XP004488270, ISSN: 0014-5793 *
PUEBLA I ET AL: "A RECOMBINANT H1 HISTONE-BASED SYSTEM FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 105, no. 3, 2003, pages 215 - 226, XP009057520, ISSN: 0168-1656 *
SIMEONI F ET AL: "Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 31, no. 11, 13 March 2003 (2003-03-13), pages 2717 - 2724, XP002984580, ISSN: 0305-1048 *
SORENSEN D R ET AL: "Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 327, no. 4, 4 April 2003 (2003-04-04), pages 761 - 766, XP004454177, ISSN: 0022-2836 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality

Also Published As

Publication number Publication date
MXPA06012605A (en) 2006-12-15
JP2007536253A (en) 2007-12-13
EP1750775A2 (en) 2007-02-14
CA2565685A1 (en) 2005-12-15
WO2005117991A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2005117991A3 (en) Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
WO2008118212A3 (en) In vivo delivery of double stranded rna to a target cell
WO2007130604A3 (en) Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
WO2006073601A3 (en) Methods and compositions for rna interference
WO2004065546A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1
WO2004011624A3 (en) Double stranded rna structures and constructs, and methods for generating and using the same
Wang et al. The tRNA-derived small RNAs regulate gene expression through triggering sequence-specific degradation of target transcripts in the oomycete pathogen Phytophthora sojae
WO2008131419A3 (en) Glycoconjugates of rna interference agents
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
WO2003080807A8 (en) Compositions and methods for suppressing eukaryotic gene expression
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2006078414A3 (en) METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE
WO2006129204A3 (en) Rnai for control of insects and arachnids
WO2007080127A3 (en) Dsrna as insect control agent
WO2008026946A3 (en) Compositions and methods for the treatment and prevention of neoplastic disorders
WO2007104570A3 (en) Nematode control
WO2009129465A3 (en) Compositions and methods for inhibiting expression of xbp-1 gene
WO2008092081A3 (en) Targeted delivery of sirna
WO2005042692A3 (en) A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
WO2007112097A3 (en) Novel signature self renewal gene expression programs
Wang et al. Tandem DNAzymes for mRNA cleavage: Choice of enzyme, metal ions and the antisense effect
WO2006066203A3 (en) Small interfering rna (sirna) molecules for modulating superoxide dismutase (sod)
MX2021004455A (en) Compositions and methods for delivering transgenes.
WO2009126896A3 (en) Methods and compositions for root knot nematode control

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012605

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007511576

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2565685

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005804803

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005804803

Country of ref document: EP